NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.
Journal articles
- Journal Article
Spratt, DE; Srinivas, S; Adra, N; Ahmed, B; An, Y; Bitting, R; Chapin, B; Cheng, HH; Cho, SY; D'Amico, AV; Desai, N; Dorff, T; Eastham, JA ...
Published in: J Natl Compr Canc Netw
May 2026
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
May 2026
Volume
24
Issue
5
Start / End Page
140 / 149
Location
United States
Related Subject Headings
- Risk Assessment
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Male
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Spratt, D. E., Srinivas, S., Adra, N., Ahmed, B., An, Y., Bitting, R., … Freedman-Cass, D. (2026). NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026. J Natl Compr Canc Netw, 24(5), 140–149. https://doi.org/10.6004/jnccn.2026.0023
Spratt, Daniel E., Sandy Srinivas, Nabil Adra, Bilawal Ahmed, Yi An, Rhonda Bitting, Brian Chapin, et al. “NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.” J Natl Compr Canc Netw 24, no. 5 (May 2026): 140–49. https://doi.org/10.6004/jnccn.2026.0023.
Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026. J Natl Compr Canc Netw. 2026 May;24(5):140–9.
Spratt, Daniel E., et al. “NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.” J Natl Compr Canc Netw, vol. 24, no. 5, May 2026, pp. 140–49. Pubmed, doi:10.6004/jnccn.2026.0023.
Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, Chapin B, Cheng HH, Cho SY, D’Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Ippolito JE, Karnes RJ, Kishan AU, Kuettel MR, Lang JM, Lee D, Lotan T, McDonald A, Morgan TM, Pessoa R, Rais-Bahrami S, Roach M, Robin T, Rosenfeld S, Scarpato KR, Seibert T, Shabsigh A, Szmulewitz R, Teply BA, Tward J, Valicenti R, VanderWeele D, Wong JK, Kovach E, Freedman-Cass D. NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026. J Natl Compr Canc Netw. 2026 May;24(5):140–149.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
May 2026
Volume
24
Issue
5
Start / End Page
140 / 149
Location
United States
Related Subject Headings
- Risk Assessment
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Male
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis